Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

Shots:

  • The companies reported that joint Livongo for diabetes and dexcom members will now receive CGM-powered insights that enables members to easily visualize their health information and understand how lifestyle decisions affect their blood glucose levels
  • In Oct’2020, Teldoc merges with Livongo while in Jan’2020 Dexcom collaborated with Livongo to integrate Dexcom’s G6 CGM system into Livongo’s applied health signals platform
  • Both the companies will launch a pilot demonstrating the impact of CGM-powered insights for people with T2D, with a broader launch across 2021

Click here ­to­ read full press release/ article | Ref: Teladoc Health | Image: Teladoc Health

The post Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D first appeared on PharmaShots.

Teladoc Health, Dexcom Offers CGM-Powered insights to People with Type 2 Diabetes

Teladoc Health, Dexcom Offers CGM-Powered insights to People with Type 2 Diabetes

What You Should Know:

– Teladoc Health and Dexcom announced an expanded
partnership on a new offering measures the impact of continuous glucose
monitoring and real-time health recommendations for people with Type 2 diabetes
at no cost.


Teladoc Health, Inc., the first and only comprehensive virtual care system, and DexCom, Inc., the leader in real-time continuous glucose monitoring (CGM), today announced that joint Livongo for Diabetes and Dexcom members will now receive CGM-powered insights. In January of 2020, Livongo, which merged with Teladoc Health in October, and Dexcom announced the first phase of their strategic relationship, a data-sharing agreement for Livongo for Diabetes members using Dexcom CGM technology.

Expanded Partnership Details

“We are excited to announce the next phase of our relationship with Teladoc Health, along with launching a commercial pilot demonstrating how Dexcom’s leading CGM combined with Teladoc Health’s data science capabilities enhance the diabetes management experience,” said Matt Dolan, senior vice president and general manager of new markets for Dexcom. “We have received powerful feedback from people with Type 2 diabetes using our technology, and through additional innovative product features, we fully anticipate that we will deliver an even greater impact.”

The expanded partnership includes two developments: 

1. Enhanced product capabilities through CGM-powered
insights, a new set of features and reports that help members more easily
visualize their health information and understand how lifestyle decisions
affect their blood glucose levels. By combining Dexcom CGM data with additional signals from
Teladoc Health, including activity data and food intake, CGM-powered insights offer members a complete health profile and recommendations
that support ongoing diabetes management.

2. A pilot program demonstrating the impact of CGM-powered
insights for people with Type 2 diabetes. Eligible members will receive an
integrated product experience including the Livongo for Diabetes program, Dexcom
CGM technology and CGM-powered insights at no cost. 

“Teladoc Health’s partnership with Dexcom further empowers whole person health through an innovative combination of advanced technology and human expertise,” said Amar Kendale, chief product officer of Teladoc Health. “Our focus is to offer a consumer experience that makes it easy, safe and affordable for people to manage their health with confidence. We are excited about our continued work with Dexcom and new features that enable smarter care, leading to measurable consumer behavior change and better health outcomes.”

Why It Matters

It is estimated that 463 million adults around the world
live with diabetes[1],
a number expected to rise to 700 million by 2045. According to the Centers for
Disease Control and Prevention, regular physical activity, weight management,
and improved blood pressure management are important factors for preventing
diabetes-related complications[2].


Digital Diabetes Market to Reach $1.5B by 2024, Research Finds

Diabetes Management Apps Global Mobile Health Solutions_7 Best Practices for Developing Successful Diabetes Mobile Apps

What You Should Know:

– The digital diabetes market is on track to reach $1.5
billion dollars by 2024, according to a new report by Research2Guidance.

– The confident growth of digital diabetes care will be driven by the growth of the global addressable market for digital diabetes services. Between 2019 and 2024, the number of diagnosed diabetics with access to smart devices is set to increase from 109 million to 180 million. 

– Digital diabetes solutions have disrupted the diabetes
care market and are changing overall chronic care, targeting not only diabetes
but also its various comorbidities, such as obesity, hypertension, and
depression.

– The report, The
Global Digital Diabetes Care Market 2020: Going Beyond Diabetes Management focuses
on the continued expansion of
digital diabetes providers into other chronic conditions (vertical expansion)
and new service opportunities (horizontal expansion), highlighting the market’s
strategic direction in the next few years. This expansion will create new
revenue opportunities, improve payer acceptance, and grow user bases beyond the
diagnosed diabetes audience.

– In the report, the Top 10 market players LifeScan Inc., Ascensia Diabetes Care, Informed Data Systems (One Drop), mySugr (Roche), H2 Inc., Livongo Health, Omada Health, Abbott, Dexcom, and Dario Health are profiled with their offerings, mobile app portfolio performance, and strategy analysis, as well as Top 10 country profiles (market opportunity size, number of solutions, downloads, number of users, Top 5 players).

Eli Lilly Collaborates with Dexcom for Diabetes Management

Shots:

  • The companies will partner to promote Lyumjev (insulin lispro-aabc injection, 100 & 200 units/mL) with Dexcom G6 CGM to aid HCPs in the US for the management of diabetes, including giving visibility to the benefits of a new mealtime insulin
  • HCPs treating T1D & T2D will be able to assess their patient’s glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, helping them to manage PPG levels. The companies will enhance HCPs education by sharing information about Lyumjev & Dexcom G6 & G6 Pro via different channels
  • Lyumjev is a formulation of insulin lispro, act by speeding up the absorption of insulin in the bloodstream and reduce A1C levels in adults with diabetes and has received the US FDA’s approval on Jun 15, 2020

    Click here ­to­ read full press release/ article | Ref: PRN | Image: IntraMed

The post Eli Lilly Collaborates with Dexcom for Diabetes Management first appeared on PharmaShots.

Current Health, Dexcom Partner to Deliver Continuous, Remote Glucose Monitoring

Current Health, Dexcom Partner to Deliver Continuous, Remote Glucose Monitoring

What You Should Know:

– Current Health has partnered with Dexcom to add continuous
glucose monitoring (CGM) capabilities to its remote patient monitoring (RPM)
platform – enhancing care and improving outcomes for diabetics.

– Dexcom CGM data will transmit directly into the Current
Health wearable and platform for review by the care management and clinical
teams, improving post-discharge and chronic care of diabetes patients outside
the hospital.

– Through this partnership, Current Health is now able to
offer a complete view of patients’ health indicators, no matter where that
patient is located – a critical need as keeping patients out of the hospital is
even more important than ever with the COVID-19 pandemic. With these insights,
healthcare providers are able to proactively address issues associated with
diabetes and provide the best possible care.


 Current Health today
announced it has partnered with Dexcom to
add continuous glucose monitoring (CGM) capabilities to Current Health’s AI-powered remote patient
monitoring (RPM)
platform. By continuously monitoring patients’ glucose
levels – largely considered the fifth vital sign – the Current Health platform
will empower health systems to secure actionable and comprehensive insights
into overall patient health, resulting in improved patient outcomes and
decreased healthcare costs.

Integration Details

As part of the integration, Dexcom CGM data will transmit
directly into the Current Health wearable and platform for review by the care
management and clinical teams, improving post-discharge and chronic care of
diabetes patients outside the hospital. Dexcom and Current Health is supplied
pre-configured and ready to go out of the box with a setup time of less than 5
minutes, the patient applies Dexcom and the Current Health wearable, so
continuous vitals and continuous glucose are immediately available for review
by the care management or clinical team. The integration will be an optional
add-on for patients using the Current Health wearable, offered first to
patients with diabetes. The integration will become widely available later this
year.

COVID-19 Underscores Need for Continuous Glucose Monitoring

With an estimated 463 million people across the globe
– or one out of every 11 adults – suffering from diabetes, health systems need
insight into patients’ whole health – including glucose levels – to best manage
at-risk patients. With people with diabetes particularly vulnerable to a
variety of illnesses, including cardiovascular disease, nerve damage and
Alzheimer’s disease – not to mention COVID-19 
healthcare providers need to be able to continuously monitor glucose levels to
ensure they can proactively address issues associated with diabetes and provide
the best possible care.

“Our focus has always been on delivering the best care to people with diabetes through continuous glucose monitoring,” said Matt Dolan, senior vice president and general manager of new markets at Dexcom. “By integrating our leading CGM system into Current Health’s RPM platform, we can expand the clinical utility of our technology and also offer a more comprehensive view into a patient’s whole health. These factors together mean that more patients will get the best care possible.”